LONDON (Reuters) – Monitoring patients at home using modern technology, so-called ‘telehealth’, is tipped as the next big thing in healthcare, but a new study by British researchers suggests it may not be worth the extra expense.

The findings will fuel controversy over the economic case for telehealth, which many information technology and telecoms companies are betting on as a multibillion-dollar market opportunity.

LONDON (Reuters) – AstraZeneca’s new chief executive announced another 2,300 job cuts in sales and administration on Thursday as he set out his stall for turning round the struggling drugmaker and returning it to growth.

The latest cutbacks mean the group will shed around a tenth of its workforce, or 5,050 jobs, by 2016 as expiring drug patents shrink sales and it faces generic competition on several top-selling medicines.

LONDON (Reuters) – AstraZeneca’s (AZN.L: Quote, Profile, Research) new chief executive announced another 2,300 job cuts in sales and administration on Thursday as he set out his stall for turning round the struggling drugmaker and returning it to growth.

The latest cutbacks mean the group will shed around a tenth of its workforce, or 5,050 jobs, by 2016 as sales shrink due to patent expires on several top-selling medicines.

LONDON (Reuters) – AstraZeneca’s (AZN.L: Quote, Profile, Research, Stock Buzz) new chief executive announced another 2,300 job cuts in sales and administration on Thursday as he set out his stall for returning the drugmaker to growth.

Pascal Soriot believes his plan to invest in smart deals to bring in new products and make the research more targeted will ultimately deliver new sales, with 2018 revenue expected to “significantly exceed” today’s market consensus of $21.5 billion.

LONDON (Reuters) – Thirty years ago, when the world faced the terrifying prospect of an untreatable disease known as AIDS, big drugmakers scented an opportunity and raced to develop new medicines.

Today, as the world confronts another crisis, this time one of antibiotic resistance, the industry is doing the opposite. It is cutting research in a field that offers little scope for making money.

LONDON (Reuters) – AstraZeneca is to cut around 1,600 jobs as it overhauls research operations and consolidates drug development work in three major centers in Britain, the United States and Sweden.

The move will see the end of drug development at the company’s Alderley Park facility in northwest England, for many years a hub of the group’s research and development (R&D) efforts, the drugmaker said on Monday.